Alterity Therapeutics Receives FDA Approval for Phase 3 MSA Trial.

Alterity Therapeutics has received positive regulatory feedback from the FDA for its planned Phase 3 trial of ATH434 in Multiple System Atrophy (MSA). The FDA supports the company's plans for clinical pharmacology and non-clinical development, reinforcing confidence in moving forward with the next stage of clinical testing. Alterity's stock was trading at A$0.0080 on the Australian Securities Exchange, showing no change from the previous session.